Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin.
SAN FRANCISCO, CA, April 23, 2015 – Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that the United States Patent and Trademark Office has issued 2 new patents based on the Company’s NANOPORTM technology. US Pat. No. 8,986,727 was issued on March 24, 2015 and covers Delpor’s microfabricated drug delivery device for the sustained release of therapeutic agents. The device uses Delpor’s proprietary NANOPORTM technology for the sustained (zero-order) release of large and small molecules for several months after subcutaneous implantation. US Pat. No. 9,005,650 was issued on April 14, 2015 and covers a method to deliver a therapeutic agent in a substantially zero-order rate for several weeks to 6 months. Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin.
Numerous therapeutic agents including GLP-1 analogues, basal insulin, human growth hormone, and interferon-alpha can benefit from long-term sustained delivery. The benefits of such delivery include improved safety, efficacy, medication adherence, as well as patient convenience in cases where frequent subcutaneous injections are required. Delpor’s unique technology is able to achieve steady (zero-order) release of agents for several months through passive diffusion (i.e., without using an osmotic pump, or any mechanical parts inside the device). A nanopore membrane, fabricated to include pores of precise dimensions, is used to control the rate of diffusion and provide a zero-order rate of release of the substance.
“These two new patents further strengthen Delpor’s intellectual property position in this key area” said Tassos Nicolaou, President and CEO of Delpor. “We believe there is an important unmet medical need related to the long term delivery of certain drugs including diabetes peptides, and we are currently pursuing a variety of products in diabetes and other areas. Our NANOPORTM technology enables the sustained release of drugs without using any mechanical parts inside the device. Such a system simplifies the manufacturing process, and allows us to substantially reduce the size of the device.”
About Delpor, Inc.